OTLK — Outlook Therapeutics Share News
0.000.00%
Last trade - 00:00- $126.42m
- $133.41m
- $1.41m
U.S. STOCKS ON THE MOVE-SentinelOne, Autodesk, Dollar Tree
U.S. STOCKS ON THE MOVE-Caterpillar, Dell, Dollar Tree
Outlook falls as Wainwright downgrades stock after US FDA declines to approve eye drug
U.S. STOCKS ON THE MOVE-Victoria's Secret, Copper miners, Dell
Outlook hits record low after US FDA declines to approve eye drug
U.S. STOCKS ON THE MOVE-Victoria's Secret, Copper miners, Dell
Outlook Therapeutics slumps after US FDA declines to approve drug for eye condition
U.S. STOCKS ON THE MOVE-Dollar General, Best Buy, Teva Pharmaceutical
U.S. STOCKS ON THE MOVE-CrowdStrike, Cheniere Energy, Outlook Therapeutics
Outlook Therapeutics slumps after US FDA declines to approve drug for eye condition
US FDA declines to approve Outlook Therapeutics' drug for eye condition (updated)
US FDA declines to approve Outlook Therapeutics' drug for eye condition
Outlook Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Outlook Therapeutics Appoints Biopharmaceutical Industry And Commercial Leader Bob Jahr As Chief Executive Officer
Brief: Outlook Therapeutics Announces SMC Recommendation Of LYTENAVA For Treatment Of Wet AMD
Brief: Outlook Therapeutics Announces Commercial Launch Of Lytenava In Germany And UK For Treatment Of Wet AMD
Brief: Outlook Therapeutics Announces Pricing Of $13.0 Million Public Offering
Outlook Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Outlook Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview